A last-minute change in plans 15 years ago put Katherine Bujold on the path to becoming the newest Canada Research Chair in McMaster’s Faculty of Science.
Bujold thought she’d finish her undergraduate degree and immediately start working as a chemist for a pharmaceutical company in her home province of Quebec.
“A career in academia was not something I ever once considered while I was an undergrad,” says Bujold, who’s now an assistant professor in the Department of Chemistry & Chemical Biology and was just appointed Canada Research Chair in Nucleic Acid Nanostructures (Tier 2).
On the eve of graduating with first-class honours with distinction from McGill University in 2011, Bujold’s job prospects disappeared overnight. Big pharma was closing research and discovery labs and eliminating hundreds of jobs across Quebec.
Bujold heeded the advice of her undergraduate research supervisor, who recommended staying at McGill for graduate studies.
The next six years changed everything for Bujold.
“I found my calling.”
Her graduate supervisor and mentor was Hanadi Sleiman, a world-renowned pioneer in the field of DNA nanoscience and precision medicine for cancer and other diseases. Bujold followed in Sleiman’s footsteps.
After graduating with a PhD in chemistry, Bujold did a stint as a research assistant with Agriculture and Agri-Food Canada and a nearly three-year postdoctoral fellowship at Northwestern University in Illinois.
Bujold moved closer to home when she was recruited to McMaster in 2020. She now leads a research group focused on driving advances in oligonucleotide chemistry (the study of building short, single or double-stranded chains of DNA or RNA), DNA self-assembly and drug delivery for precision medicine.
One of her students was just recruited by her former grad supervisor. “I took it as a sign that I’m doing something right,” says Bujold.
“I’m having a lot of fun at McMaster. It’s the best job I’ve ever had. I’m working with amazing students and colleagues and there are still so many unknowns left to explore.”
Bujold and her students are also doing important work. They’re discovering new ways to reboot or silence broken cells using synthetic nucleic acids and DNA nanostructures.
That work includes assembling the first DNA “nanosuitcase” that contains genetic material capable of safely and precisely destroying a specific cell before it can make an unwanted protein.
That’s an impressive feat, given that our bodies are made up of around 36 trillion cells that work together to keep us alive. Within each cell are approximately six billion DNA base pairs that serve as the cell’s biological user manuals.
Those coded instructions can be lost or scrambled when a single DNA strand is damaged. If a cell can’t fix what’s broken or botches the repair job, bad things can happen, ranging from the death of the cell to a permanent mutation or uncontrolled tumour growth.
The synthetic nucleic acids being developed in Bujold’s lab contain replacement instructions for these broken and rogue cells. To deliver those instructions into a cell, Bujold’s team has figured out how get around a cell’s ever-vigilant self-defence system.
Cell-autonomous immunity repels the never-ending and relentless hordes of external invaders like bacteria, viruses and fungi.
“Without these defenses, healthy cells would be overrun and hijacked,” says Bujold. “We’d get infected by literally everything. Our bodies would be overwhelmed by diseases and our lives would end almost immediately.”
But what naturally protects our cells also repels the nucleic acids Bujold and her research group are developing in the lab.
That’s why they are focused on developing new kinds of nucleic acids that can either trick a cell into lowering its defenses or bypass those fortress-like barricades altogether.
Bujold hopes the research happening in her lab today will, within the next decade, lead to discoveries of innovative nucleic acid delivery materials with the potential to revolutionize the treatment of infectious diseases, rare and genetic disorders and cancer.
“With nucleic acids, we can go in and immediately fix or regulate diseases at the genetic blueprint level rather than spend a lifetime managing symptoms,” she says.
“I think the work we’re doing at McMaster will contribute something meaningful that will have tremendous therapeutic benefits.”
These discoveries have Bujold revisiting and updating the plans she was forced to change back in 2011. Instead of joining a pharmaceutical company, she’s looking to collaborate with industry partners to turn the discoveries happening at the lab bench into clinical breakthroughs at the bedside.
“The work we’ve been doing in the lab has been happening at the discovery stage — we’re testing ideas that may be a bit too far out there to be relevant as a drug. But we’re quickly approaching the engineering and development stage.”
And then there’s Bujold’s work with PentaPink Biotechnology, a made-at-Mac start-up that’s pioneering the next generation of biopolymer therapeutics. Bujold is serving as co-founder and chief science officer in the company launched by departmental colleague and biophysics professor Maikel Rheinstädter.
“I couldn’t have asked for — or even dreamed of — a more rewarding and fulfilling career.”
Launched by the Dean’s Office, the Profiles in Discovery series showcases the assistant and associate professors who represent the future of the research enterprise in the Faculty of Science.